‘Blue Sunday’ 2023 – M.E. myself and I

Once again, I’m hosting my Tea Party For M.E. for people with M.E. and their family and friends. I strongly believe that we need and deserve as dedicated day of fundraising, but also a day where we can come together to mark and celebrate our resilience and our strength in the face of this cruel…

EverythingOpen: connecting open* communities – Kathy Reid

Mid-March of this year saw the very first EverythingOpen conference, held in Naarm/Melbourne at the Melbourne Exhibition and Convention Centre. Unfortunately, I had some PhD commitments, and only managed to get there for the conference dinner, but was able to catch up afterwards via the conference videos – and this blog post is a recap…

#MillionsMissing 2023 – #MillionsMissing

#MillionsMissing 2023 will be held at the Washington Monument on the National Mall in Washington, DC on May 12th that will feature an art installation and press conference. This year, #MEAction in partnership with Body Politic, will host #MillionsMissing 2023 to demand bold, urgent governmental action for the millions of people living with myalgic encephalomyelitis…

RFA-AI-23-028: Fundamental Research to Understand the Mechanisms of Neurotropic Virus-mediated Disease (R01 Clinical Trial Not Allowed)

The purpose of this Notice of Funding Opportunity (NOFO) is to promote basic research to better understand the mechanisms underlying viral invasion of the central nervous system (CNS), virus- and/or host immune-mediated neuropathogenesis, and the associated clinical manifestations for emerging and re-emerging neurotropic viruses. Source: RFA-AI-23-028: Fundamental Research to Understand the Mechanisms of Neurotropic Virus-mediated…

Pragmatica-Lung Study opens for patient enrollment – NCI

The National Cancer Institute, part of the National Institutes of Health (NIH), has helped launch a phase 3 randomized clinical trial (NCT05633602) of a two-drug combination to treat patients with advanced non-small cell lung cancer (NSCLC). Called the Pragmatica-Lung Study (or S2302), this is one of the first NCI-supported clinical trials to use a trial…

Risk of Protection Failure with Certain O&M Halyard Surgical N95 Respirators, Surgical Masks, and Pediatric Face Masks: FDA Safety Communication | FDA

Date Issued: April 12, 2023 The U.S. Food and Drug Administration (FDA) is recommending consumers, health care providers, and facilities to not use certain surgical N95 respirators manufactured by O&M Halyard, and to use caution with certain surgical masks and pediatric face masks manufactured by O&M Halyard. The FDA is aware of laboratory test results…